Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group
Guideline
OA: bronze
CC0
⤵ 65 in-corpus citations
AI-generated summary
This paper reviews the use of add-back therapy with gonadotropin-releasing hormone agonists for endometriosis treatment and seeks to establish a consensus on best practices.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To reach a consensus on the role of add-back therapy for patients with endometriosis administered GnRH agonists (GnRH-a).
DESIGN: Results of consensus conference reviewing MEDLINE search of English language abstracts of both prospective and retrospective series.
SETTING: Consensus conference of 31 specialists in gynecologic surgery and reproductive endocrinology.
PATIENT(S): Patients with symptomatic endometriosis who were candidates for GnRH-a therapy in treatment courses ranging in duration from 6 to 12 months.
INTERVENTION(S): Oral steroidal and nonsteroidal add-back regimens.
MAIN OUTCOME MEASURE(S): Alteration in painful symptoms, extent of disease, vasomotor symptoms, bone mineral density, and serum lipid profile.
RESULT(S): When added to GnRH-a for 6 months, both 2.5 mg of norethindrone and 0.625 mg of conjugated equine estrogens with 5 mg/d of medroxyprogesterone acetate provide effective relief of vasomotor symptoms and decrease but do not eliminate bone mineral density loss. During 12 months of GnRH-a therapy, bone mineral density loss is eliminated effectively with an add-back of 5 mg of norethindrone acetate alone or in conjunction with low-dose conjugated equine estrogens. Organic bisphosphonates also may play a role.
CONCLUSION(S): In patients with symptomatic endometriosis, the efficacy of GnRH agonists may be preserved and therapy prolonged while overcoming hypoestrogenic side effects with the use of appropriate add-back regimens.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (20)
- Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial via openalex
- Can hormone replacement therapy be used during medical therapy of endometriosis? via openalex
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? via openalex
- Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group via openalex
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group via openalex
- Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis via openalex
- Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate via openalex
- Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group via openalex
- W6717624033 via openalex
- W133578770 via openalex
- W201040832 via openalex
- W2004430776 via openalex
- W2123876576 via openalex
- W2342833836 via openalex
Cited by (50)
- Weighing up GnRH agonist therapy for endometriosis: outcomes and the treatment paradigm 2025
- Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis 2025
- Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023 2024
- The Double Engines and Single Checkpoint Theory of Endometriosis 2022
- Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids 2022
- A Preliminary Study on the Effects of Black Cohosh Preparations on Bone Metabolism of Rat Models With GnRH-a-Induced Peri-Menopausal Symptoms 2022
- Role of medical treatment of endometriosis 2021
- Endometriosis 2021
- Endometriose Aspectos clínicos do diagnóstico ao tratamento 2021
- Neue Behandlungsmöglichkeiten der Endometriose mit GnRH-Antagonisten 2020
- Neue Behandlungsoptionen mit GnRH-Antagonisten bei Endometriose und Uterus myomatosus 2020
- Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis 2020
- Endometriosis 2019
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
- Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial 2015
- Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone 2015
- The effect of macrophages on fibroblast activity and lesion development in mouse models of endometriosis. 2014
- The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with estrogen-progestogen add-back therapy in endometriosis patients of reproductive age 2013
- Endometriose 2013
- PENATALAKSANAAN ENDOMETRIOSIS 2012
- The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis 2012
- Endometriosis 2012
- Quality of life according to add-back therapy during GnRH agonist treatment in endometriosis patients 2012
- Evidence-based long-term management of endometriosis: Medical therapy and treatment of infertility 2011
- Clinical management of endometriosis 2011
- Gonadotropin releasing hormone agonists: Expanding vistas 2011
- The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis 2010
- Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? 2010
- Add-back therapy use and its impact on LA persistence in patients with endometriosis 2010
- Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications 2010
- Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain 2009
- GnRH-Analoga und Add-back-Verfahren 2008
- Patientinnenzentrierte Aspekte der Endometriose 2008
- Endometriose 2007
- Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis 2007
- Endometriosis 2007
- Endometriosis and Adenomyosis 2007
- Is it of value to treat endometriosis prior to IVF 2006
- The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with tibolone add-back therapy in endometriosis patients of reproductive age 2006
- Long-term fracture risk among women with proven endometriosis 2006
- Tratamento da endometriose 2006
- Add-back therapy in the treatment of endometriosis-associated pain 2004
- Evaluation and management of breast pain 2004
- One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial 2004
- Novel targets for the treatment of endometriosis 2004
- Patientinnenzentrierte Aspekte der Endometriose 2003
- Medical Therapy for Endometriosis 2003
- Endometriosis: treatment strategies 2003
- Evaluation and management of women with endometriosis 2003
- Rezidivierende Endometriose?ein Kofaktor der vorzeitigen Menopause? 2003
Source provenance
- europepmc
- last seen: 2026-11-15T09:34:25.365398+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T20:58:50.057178+00:00
License: CC0
· commercial use OK